Record PAT Hides a Pipeline in Crisis

On the surface, Gretex's Q1 FY27 result looks like a home run: ₹37.5 Cr in revenue (+70.7% YoY) and ₹12.8 Cr in net profit (+1240% YoY). But the 17.5× gap between revenue growth and profit growth is not a sign of scale — it's a sign of operating leverage. And leverage works in both directions. The core issue: the IPO advisory business, which accounts for the majority of revenue and the lion's share of profit, faced a structural headwind in Q1. Mainboard IPO volumes collapsed from 108 in FY26 to just 8 in Q1 FY27 — a 71% year-on-year decline. Gretex still grew profit +1240% because it captured market share and its broking subsidiary stepped up. But management's silence on forward guidance reveals the real concern: they don't expect this to last.

The 1240% PAT growth tells the story of operating leverage, not business growth. Revenue grew 71%, but profit grew 17.5× faster. Here's the mechanism: IPO advisory fees are high-margin (think 30–40% margin on advisory revenue). Broking revenue is lower-margin (single-digit to low-teens margin). In Q1, with IPO volumes at cyclical lows, Gretex's broking and SME segments — which are structurally lower-margin — stepped in to fill the gap. The company's high fixed costs (advisory staff, infrastructure, regulatory compliance) were spread over a slightly larger revenue base, compressing unit costs and lifting the operating margin to a stunning 45.7%. But this is not sustainable. If IPO volumes stay depressed (management's Q2 guidance of 'minimum 3–4 listings' suggests continued softness), advisory revenue will soften faster than broking revenue can compensate, and margins will compress back toward the mid-20s from the current 33.6% NPM. The fact that management did not restate or raise their prior 40–45% PAT margin guidance — and instead provided zero guidance at all — is a signal they expect this compression.

The stock closed at ₹469.05 as of 2026-07-08, trading well above its 20-day (₹439.97) and 50-day (₹410.48) moving averages, and substantially above its 200-day average (₹333.52). Year-to-date, the stock has rallied 117.91% off its 52-week low of ₹215.25, though it sits 8.03% below its all-time high of ₹510. The technical picture is bullish — RSI at 64.1 (neutral zone) and volume trend normal — but the stock is trading near cyclical highs, leaving little room for disappointment. FII ownership ticked up to 1.99% from 1.10% in the prior quarter, a modest but positive shift suggesting some institutional appetite. However, the most recent bulk activity is mixed: Mansukh entities (likely broking houses) have been active on both sides (buying and selling) at ₹517–₹525 levels, while Bonanza Agency sold 3.75 lakh shares at ₹530.10 — right near the all-time high. This selling at the peak by a larger entity is a subtle bearish signal and suggests informed sellers see limited upside from current levels. The bulk activity is not on the scale of major forced selling, but it's worth monitoring.

In sum: the market has priced in a strong recovery narrative (stock up 118% off lows, near ATH) but the fundamentals have deteriorated (IPO pipeline -71%, guidance withdrawn, margins at risk). The price action reflects optimism about diversification and broking growth, but does not yet reflect the full impact of IPO volume compression. If Q2 volumes come in at 'minimum 3–4 listings' as guided — well below the historical 27+ per quarter — the current valuation looks stretched.

The honest read: Q1 was excellent operationally. Revenue grew 71%, profit grew 1240%, market share was captured, and the strategic pivot (mainboard focus, broking listing, AIF entry) is sound. But the quarter was a leverage story, not a growth story. The IPO market is down 71% YoY, and Gretex's core advisory business rode that decline while broking and SME picked up the slack. This is not a sustainable mix. Management's withdrawal of all forward guidance — stark contrast to prior calls' quantified targets — is a signal they see margin compression ahead. The stock is priced for optimism (up 118% off lows, near ATH), but the fundamentals show a business adapting to a structurally weaker core. Execution is strong, but the juice may be nearly priced in. A Hold rating best captures the risk-reward: good management, good execution, but uncertain margin trajectory in a depressed IPO environment. The next two quarters will tell if diversification (broking, AIF) can offset advisory decline — if not, the stock re-rates lower.

From here, the organic net profit margin (adjusted for any non-recurring items, though none have been disclosed) is the number to watch quarter-by-quarter. If Gretex can hold margins in the 30–33% range as IPO advisory normalizes, the diversification (broking, AIF) story plays out and the stock has room to re-rate higher. If margins compress to the low-to-mid 20s, it signals the advisory decline is structural, broking is not filling the gap fast enough, and the stock has downside. The 1240% PAT jump in Q1 masks a business in transition — the next three quarters will determine if the transition succeeds or if it's a value trap. Right now, the market is pricing success (stock near ATH); the odds are closer to 50–50.